Literature DB >> 14615845

[Ablative procedures in surgical treatment of malignant bone tumors].

P-U Tunn1, H Delbrück, P M Schlag.   

Abstract

Limb-sparing surgery is the treatment of choice for primary malignant bone tumors. However, ablative procedures cannot always be avoided. The indication to sacrifice the limb depends on localization, size, and biology of the tumor and does not represent failure of treatment primarily. Amputation of the limb is necessary if there is no other operative procedure to achieve negative surgical margins even if all adjunctive therapeutic options have been considered. Primary ablative resections may be indicated with both curative and palliative intent. Secondary ablative procedures mainly result from local recurrence. Late complications of endoprosthetic or allograft reconstruction also may necessitate ablative surgery. In this paper, general guidelines for ablative surgeries are presented. Following amputation, early prosthetic repair of the extremity is the goal. In those patients with consolidated stump development definitive prosthesis should be adapted. Results of hemipelvectomy and forequarter amputation from our institution are reported. However, this group of patients together with those undergoing shoulder exarticulation and forequarter amputation represent situations with no prosthetic repair possible. The loss of an extremity induces disability and restriction of ego, physical integrity, and quality of life. However, it should be borne in mind that amputation could represent the only chance of cure sometimes. Sharing the decision-making between patient and physician for this procedure is an important step to develop confidence in the therapeutic process. In this setting, direct contact between patients being confronted with the option of an amputation and those patients having already undergone rehabilitative procedures might be very useful.

Entities:  

Mesh:

Year:  2003        PMID: 14615845     DOI: 10.1007/s00132-003-0547-6

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  29 in total

1.  Function and complications after ablative and limb-salvage therapy in lower extremity sarcoma of bone.

Authors:  A J Renard; R P Veth; H W Schreuder; C J van Loon; H S Koops; J R van Horn
Journal:  J Surg Oncol       Date:  2000-04       Impact factor: 3.454

2.  [The limits of saving the extremity--amputation versus resection].

Authors:  R Kotz; P Ritschl; D Kropej; C Schiller; C Wurnig; M Salzer-Kuntschik
Journal:  Z Orthop Ihre Grenzgeb       Date:  1992 Jul-Aug

3.  Limb salvage and outcome of osteosarcoma. The University of Muenster experience.

Authors:  N J Lindner; O Ramm; A Hillmann; R Roedl; G Gosheger; C Brinkschmidt; H Juergens; W Winkelmann
Journal:  Clin Orthop Relat Res       Date:  1999-01       Impact factor: 4.176

4.  Complications and outcome of external hemipelvectomy in the management of pelvic tumors.

Authors:  J P Apffelstaedt; D L Driscoll; J E Spellman; A F Velez; J F Gibbs; C P Karakousis
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

5.  [Ablative and extremity salvage tumor surgery of the lower extremity--a 10 year comparison].

Authors:  R Rödl; U Pohlmann; G Gosheger; C Hoffmann; B Leidinger; N Lindner; W Winkelmann
Journal:  Z Orthop Ihre Grenzgeb       Date:  2001 May-Jun

Review 6.  Current treatment of osteosarcoma.

Authors:  W S Ferguson; A M Goorin
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

7.  Osteosarcoma of the pelvis. A clinical and histopathological study of twenty-five patients.

Authors:  M Fahey; S S Spanier; R A Vander Griend
Journal:  J Bone Joint Surg Am       Date:  1992-03       Impact factor: 5.284

8.  Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma.

Authors:  M Sluga; R Windhager; S Lang; H Heinzl; S Bielack; R Kotz
Journal:  Clin Orthop Relat Res       Date:  1999-01       Impact factor: 4.176

9.  Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy.

Authors:  G Bacci; S Ferrari; A Longhi; S Perin; C Forni; N Fabbri; N Salduca; M Versari; K V Smith
Journal:  Eur J Cancer       Date:  2001-01       Impact factor: 9.162

Review 10.  [Malignant bone tumors--is amputation still necessary today?].

Authors:  F Hefti
Journal:  Schweiz Rundsch Med Prax       Date:  1993-03-16
View more
  1 in total

1.  Total hip replacement for proximal femoral tumours: our midterm results.

Authors:  V A Sokolovski; V P Voloshin; M D Aliev; V S Zubikov; S A Saravanan; D V Martynenko; D V Nisichenko; K N Strelnikov
Journal:  Int Orthop       Date:  2006-04-12       Impact factor: 3.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.